You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-RUNX1 / AML1 antibodySee all RUNX1 / AML1 primary antibodies ...
  • Description
    Rabbit polyclonal to RUNX1 / AML1
  • SpecificityDetects endogenous levels of total RUNX1 / AML1 protein.
  • Tested applicationsELISA, WB more details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic non-phosphopeptide derived from human RUNX1 / AML1 around the phosphorylation site of Serine 303 (PISPG)

  • Positive controlExtracts from Jurkat cells

Properties

Applications

Our Abpromise guarantee covers the use of ab55363 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ELISA ELISA: 1/20000.
WB WB: 1/500 - 1/1000. Predicted molecular weight: 49 kDa.

Target

  • FunctionCBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificityExpressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
  • Involvement in diseaseNote=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
    Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
    Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.
  • Sequence similaritiesContains 1 Runt domain.
  • DomainA proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.
  • Post-translational
    modifications
    Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
    Methylated.
  • Cellular localizationNucleus.
  • Target information above from: UniProt accession Q01196 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      Acute myeloid leukemia 1 antibodyAcute myeloid leukemia 1 protein antibodyalpha subunit core binding factor antibody
      AML 1 antibodyAML1 antibodyAML1 EVI 1 antibodyAML1 EVI 1 fusion protein antibodyAml1 oncogene antibodyAMLCR 1 antibodyAMLCR1 antibodyCBF alpha 2 antibodyCBF-alpha-2 antibodyCBFA 2 antibodyCBFA2 antibodyCore binding factor alpha 2 subunit antibodyCore binding factor runt domain alpha subunit 2 antibodyCore-binding factor subunit alpha-2 antibodyEVI 1 antibodyEVI1 antibodyHGNC antibodyOncogene AML 1 antibodyOncogene AML-1 antibodyOTTHUMP00000108696 antibodyOTTHUMP00000108697 antibodyOTTHUMP00000108699 antibodyOTTHUMP00000108700 antibodyOTTHUMP00000108702 antibodyPEA2 alpha B antibodyPEA2-alpha B antibodyPEBP2 alpha B antibodyPEBP2-alpha B antibodyPEBP2A2 antibodyPEBP2aB antibodyPolyomavirus enhancer binding protein 2 alpha B subunit antibodyPolyomavirus enhancer-binding protein 2 alpha B subunit antibodyRun1 antibodyRunt related transcription factor 1 antibodyRunt-related transcription factor 1 antibodyRUNX 1 antibodyRunx1 antibodyRUNX1_HUMAN antibodySL3 3 enhancer factor 1 alpha B subunit antibodySL3-3 enhancer factor 1 alpha B subunit antibodySL3/AKV core binding factor alpha B subunit antibodySL3/AKV core-binding factor alpha B subunit antibody
    see all

Anti-RUNX1 / AML1 antibody images

  • All lanes : Anti-RUNX1 / AML1 antibody (ab55363) at 1/500 dilution

    Lane 1 : extracts from Jurkat cells with no immunizing peptide
    Lane 2 : extracts from Jurkat cells with immunizing peptide


    Predicted band size : 49 kDa

References for Anti-RUNX1 / AML1 antibody (ab55363)

ab55363 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab55363.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"